UKPDS shows glucose control and metformin legacy effects


The UKPDS 10-year post-trial monitoring results were presented at the 44th EASD meeting in Rome on Wednesday 10th September 2008.

They showed continuing benefit of earlier improved glucose control, with emergent significant risk reductions for myocardial infarction and all-cause mortality, despite loss of within trial blood glucose and antihyperglyaemic therapy differences - a legacy effect.

A legacy effect was seen also for earlier metformin therapy.

No legacy effect was seen for earlier improved blood pressure therapy.

See link below for further details, publication of UKPDS paper 80 showing the glucose study finding, and UKPDS paper 81 showing the blood pressure study findings.